Heidelberg Pharma AG (HPHA)

Currency in EUR
2.820
-0.020(-0.70%)
Closed·
HPHA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.7202.820
52 wk Range
2.3305.360
Key Statistics
Bid/Ask
2.75 / 2.83
Prev. Close
2.84
Open
2.75
Day's Range
2.72-2.82
52 wk Range
2.33-5.36
Volume
1.66K
Average Volume (3m)
4.25K
1-Year Change
-6.6225%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HPHA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.750
Upside
+139.36%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Heidelberg Pharma AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.750
(+139.36% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Heidelberg Pharma AG Earnings Call Summary for Q4/2025

  • Heidelberg Pharma reported Q4 2025 net loss of EUR 42.3M with EPS of -0.91 EUR; revenue fell 64% YoY to $3.55M amid strategic restructuring.
  • R&D expenses surged 77.5% to EUR 38.7M as company refocused on lead program HDP-101; operating costs jumped 50.3% to EUR 49.0M year-over-year.
  • Dr. Dongzhou Jeffery Liu appointed as new CEO; company extended cash runway to mid-2027 through non-dilutive financing and cost optimization.
  • HDP-101 clinical trials show promising results with interim readouts expected mid-2026; stock rose 21% YTD despite financial challenges.
  • Company maintains strong liquidity with 5.85 current ratio and more cash than debt, though faces risks from high burn rate and trial outcome dependency.
Last Updated: 26/03/2026, 14:20
Read Full Transcript

Earnings

Latest Release
30/04/2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare HPHA to Peers and Sector

Metrics to compare
HPHA
Peers
Sector
Relationship
P/E Ratio
-−2.9x−0.5x
PEG Ratio
-−0.030.00
Price/Book
-0.9x2.6x
Price / LTM Sales
-4.5x3.3x
Upside (Analyst Target)
137.7%125.0%47.1%
Fair Value Upside
Unlock−2.2%6.2%Unlock

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company’s lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
340.35K0.73%966.59K
Other Institutional Investors
35.74M76.39%101.49M
Public Companies & Retail Investors
10.71M22.89%30.41M
Total
46.78M100.00%132.87M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
dievini Hopp BioTech holding GmbH & Co. KG41.62%19,472,09255,301
Huadong Medicine Co., Ltd34.77%16,265,13746,193

People Also Watch

45.500
PSAGn
+1.11%
906.00
KSBG
-9.40%
34.400
TTRGn
+0.15%
16.850
LEIG
-0.88%
9.620
HNL
+4.57%

FAQ

What Is the Heidelberg Pharma AG (Xetra: HPHA) Share Price Today?

The Heidelberg Pharma AG stock price today is 2.820 EUR.

What Stock Exchange Does Heidelberg Pharma AG (HPHA) Trade On?

Heidelberg Pharma AG is listed and trades on the Frankfurt Stock Exchange.

What Is the Ticker (Stock Symbol) for Heidelberg Pharma AG?

The stock symbol (also called a 'ticker') for Heidelberg Pharma AG is "HPHA."

What Is the Current Heidelberg Pharma AG Market Capitalisation?

As of today, Heidelberg Pharma AG (Xetra: HPHA) market cap is 131.930M EUR.

What Is Heidelberg Pharma AG's (HPHA) Earnings Per Share (TTM)?

The Heidelberg Pharma AG EPS is currently -0.906 (Trailing Twelve Months).

When Is the Next Heidelberg Pharma AG Earnings Date?

Heidelberg Pharma AG's next earnings report will be released on 15/07/2026.

Is HPHA a Buy or Sell From a Technical Analyst Perspective?

Based on today's Heidelberg Pharma AG moving averages and other technical indicators, the daily buy/sell signal for HPHA stock is Sell.

How Many Times Has Heidelberg Pharma AG Stock Split?

Heidelberg Pharma AG has split 9 times. (See the HPHA stock split history page for full effective split date and price information.)

How Many Employees Does Heidelberg Pharma AG Have?

Heidelberg Pharma AG has 114 employees, based on their latest Companies House report.

What is the current trading status of Heidelberg Pharma AG (Xetra: HPHA)?

As of 05/05/2026, Heidelberg Pharma AG (HPHA) is trading at a share price of 2.820 EUR, with a previous close of 2.840 EUR. The stock has fluctuated within a day range of 2.720 EUR to 2.820 EUR, while its 52-week range spans from 2.330 EUR to 5.360 EUR.

What Is Heidelberg Pharma AG (HPHA) Price Target According to Analysts?

The average 12-month price target for Heidelberg Pharma AG is 6.750 EUR, with a high estimate of 8 EUR and a low estimate of 5.5 EUR. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +139.36% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.